Ibuprofen B. Braun (Ibuprofen)

Ibuprofen works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which blocks the synthesis of prostaglandins. Lower prostaglandin levels decrease pain signaling, lower the hypothalamic temperature set‑point, and reduce inflammation at the site of injury.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and therapeutic goals. Healthcare professionals follow local guidelines and product labeling to select an appropriate regimen.

Safety data for intravenous ibuprofen in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and the necessary import documentation.

Compared with alternatives such as ketorolac injection, intravenous ibuprofen offers a similar analgesic and antipyretic profile but may have a slightly lower risk of renal adverse effects at equivalent doses. Choice of agent depends on individual patient factors, institutional protocols, and cost considerations.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to use, inspect the solution for particulate matter or discoloration and follow aseptic techniques during preparation and administration.

Ibuprofen B. Braun is given by intravenous infusion. The solution is typically diluted in compatible IV fluids and infused over a period of 15‑30 minutes, depending on the prescribed dose and the patient’s clinical status. Administration should be performed by qualified healthcare personnel.

The most serious adverse events include gastrointestinal bleeding, acute renal failure, and severe allergic reactions such as anaphylaxis. Prompt recognition and management of these events are essential, and patients should be monitored closely, especially if they have pre‑existing risk factors.

Patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal ulcer disease, severe renal impairment, uncontrolled heart failure, or those receiving anticoagulant therapy with a high bleeding risk should avoid this product unless a clinician determines that benefits outweigh the risks.